For certain European nations, OECD has developed a Series on Principles of Good Laboratory Practice (GLP) and Compliance Monitoring. These principles share with the U.S. GLPs the intention to:

• A. Control and direct the operations of research and testing facilities
• B. Increase the rate of clinical trials
• C. Promote international trade
• D. Standardize pharmacovigilance

Answer: (A)

GLP principles are about ensuring quality and reliability of laboratory data by tightly controlling how research and testing are planned, conducted, and documented. The OECD series mirrors the U.S. GLPs in focusing on directing and supervising the operations of research and testing facilities—things like qualified personnel, appropriate facilities and equipment, standard operating procedures, study plans, proper recording, and accurate reporting. This shared aim is to make safety data trustworthy and comparable across labs and countries.

The other ideas don’t fit because GLP isn’t about speeding up clinical trials, boosting international trade, or standardizing pharmacovigilance. It’s not a trade or market mechanism, and pharmacovigilance deals with post-market safety monitoring rather than preclinical data integrity.